GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seelos Therapeutics Inc (FRA:NXE0) » Definitions » Institutional Ownership

Seelos Therapeutics (FRA:NXE0) Institutional Ownership : 7.40% (As of Jun. 06, 2024)


View and export this data going back to . Start your Free Trial

What is Seelos Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Seelos Therapeutics's institutional ownership is 7.40%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Seelos Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Seelos Therapeutics's Float Percentage Of Total Shares Outstanding is 98.60%.


Seelos Therapeutics Institutional Ownership Historical Data

The historical data trend for Seelos Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seelos Therapeutics Institutional Ownership Chart

Seelos Therapeutics Historical Data

The historical data trend for Seelos Therapeutics can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 10.90 8.86 6.87 7.31 10.24 8.11 8.03 8.59 8.57 7.40

Seelos Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Seelos Therapeutics (FRA:NXE0) Business Description

Traded in Other Exchanges
Address
300 Park Avenue, 2nd Floor, New York, NY, USA, 10022
Seelos Therapeutics Inc is a clinical-stage biotechnology company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders.

Seelos Therapeutics (FRA:NXE0) Headlines

No Headlines